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Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the US. The majority (~85%)
of GISTs possess gain-of-function mutations in KIT or PDGFRA, causing constitutive activation of the kinase receptor. GIST
management has been transformed by the identification of tumor driver mutations leading to unprecedented disease
control of advanced GIST with the introduction of imatinib mesylate (IM). Despite IM’s efficacy, most patients experience
primary and/or secondary resistance within 2 y of treatment. Additional therapies and methods to optimize screening of
novel approaches in preclinical studies are warranted. Clinically, treatment efficacy is typically assessed using Response
Evaluation Criteria In Solid Tumors (RECIST) guidelines or Choi criteria. Both require a period of time on therapy before
changes indicative of response can be observed. In addition, neither informs directly about cell death. We evaluated the
use of molecular imaging technology in an animal model using near-infrared (NIR) imaging probes together with threedimensional fluorescence molecular tomography (FMT) for assessing therapeutic response and ultimately optimizing
our understanding of the biologic effects of these agents. We determined the potential of NIR probes (PSVueTM794 and
cell-penetrating KcapQ647) for detecting distinct markers of apoptosis and compare this to tumor size measured by MRI
in response to IM treatment in GIST-T1 xenografts. Our studies revealed statistically significant increases in apoptosis due
to IM treatment using both probes as early as 24 h post IM treatment which was confirmed by IHC. Molecular imaging will
allow for faster and more effective screening of novel therapies in preclinical GIST models.

Introduction
Gastrointestinal stromal tumor (GIST) is the most common
mesenchymal tumor of the gastrointestinal tract, afflicting an
estimated 3000 to 6000 new patients each year.1 It typically presents between the fifth and sixth decade of life with abdominal
pain, symptoms of anemia or acute bleeding. Management of the
disease has been transformed by the identification of activating
mutations in the tyrosine kinase receptors, KIT and PDGFRA,
leading to the unprecedented disease control of advanced GIST
with the introduction of the kinase inhibitors imatinib mesylate (IM), sunitinib malate, and regorafenib. Response to treatment has been correlated with the site of the mutation in KIT or
PDGFRA, with those tumors carrying mutations in exons 11 and
12, respectively, having the best response to therapy.2 The success
of IM in GIST has been tempered by the fact that treatment in the
advanced disease setting only increases the median time to tumor
progression by approximately 2 y. Reasons identified for this limited therapeutic efficacy include decreased effectiveness of IM for

KIT mutations outside of exon 11 and in tumors lacking mutations in KIT and PDGFRA. Furthermore, GISTs that progress
are likely to have secondary mutations in KIT or PGDFRA and/
or epigenetic changes that act together to create a more aggressive
tumor. Sunitinib therapy offers a median of an additional 5 mo
delay to tumor progression3 and is currently used as the secondline therapy. Regorafenib, FDA approved in February 2013, is
now the third-line drug of choice with a median progression free
survival (PFS) of 4.8 mo.4,5 However, it is clear that additional
therapies are still needed and methods to optimize screening of
novel approaches are warranted.
In clinical trials, efficacy of therapies is measured utilizing
RECIST criteria, a measure of change in tumor size over time
using clinical imaging technologies (CT, MRI). RECIST, which
looks at tumor size only, has been critiqued as not correlating with
clinical improvement, metabolic response by [18F] fluorodeoxyglucose-positron emission tomography (FDG-PET), or pathologic response. For example, patients with IM-treated tumors
that remain stable in size have similar survival to those with
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Results
To develop methods for assessing novel therapeutic agents
or combinations of agents to effectively treat GIST, we sought
to evaluate whether we could successfully visualize treatmentrelated apoptosis in GIST xenografts using a treatment known
to be effective both clinically and in this model. To do this, we
utilized three NIR probes: IntegriSense680, PSVueTM794, and
KcapQ647, in combination with FMT imaging. In preliminary
pilot studies, we found that IntegriSense680, which detects the
tumor-associated integrin αvβ3, localized strongly and specifically
to the GIST xenograft tumors and could therefore be used to
determine the three dimensional region of interest (ROI) in the
FMT data sets. This was necessary because the signal from the
apoptosis sensing probes was not as strong, and did not localize
as specifically to the tumors as the IntegriSense680 probe. The
time for optimal imaging (maximum signal in the tumor as compared with the whole-body background) for the IntegriSense680
probe was determined to be 96 h post-injection. We then performed additional preliminary studies using the PSVueTM794
and KcapQ647 NIR probes, in separate studies, to determine
optimal time points for imaging following probe injection by
acquiring longitudinal images. To do this, 8 mice with GIST-T1
cell xenografts (4 vehicle and 4 IM-treated) were given retroorbital injections of either PSVueTM794 or KcapQ647 in combination with IntegriSense680. FMT Images were acquired at 0.5,
1, 3, 6, 12, 18, and 24 h post-probe injection. With both probes,
all IM-treated GISTs had significantly more probe signal than
vehicle-treated tumors at both 24 h post-IM treatment (Fig. 1)
as well as 1 wk post-treatment, with the optimal imaging times
of 18 h post-injection for PSVueTM794 and 1 h post-injection for
KcapQ647. Following these pilot studies, a larger cohort of mice
(n = 14) bearing GIST-T1 xenografts were randomized into two
treatment groups: vehicle and IM. These mice were injected with

all three probes (IntegriSense680, PSVueTM794, KcapQ647)
at the previously determined optimal imaging times, and were
treated with vehicle or IM (50 mg/kg daily). Twenty-four hours
post treatment, all mice were imaged in the 645, 680, and 750
nm channels to determine individual probe retention in the
tumor. This imaging schedule was repeated in these mice one
week post treatment. To improve the power to detect a difference
between vehicle and IM treated animals, we combined this data
with data from both aforementioned studies. As outlined earlier,
the GEE methodology was used to model treatment effect and
time on apoptotic activity, adjusted for potential batch effects in
the experiment. A statistically significant increase in the rate of
apoptotic activity due to IM treatment (compared with control)
was observed (P value = 0.002) using data from the KcapQ647
probe. However, there was neither a significant change in apoptotic activity with time (P value = 0.69) nor treatment effect with
time (P value = 0.41). Similarly, a statistically significant increase
in the rate of apoptotic activity due to IM treatment (compared
with control) was observed (P value = 1.41e−04) using data from
the PSVueTM794 probe. Again, there was neither a significant
change in apoptotic activity with time (P value = 0.11) nor treatment effect with time (P value = 0.21). Figure 2A and B display the growth curves for the IM treated and vehicle treated
control groups based on data obtained using the KcapQ647 and
PSVueTM794 probes, respectively. It is evident that IM treatment increases apoptotic activity (as measured by both probes)
compared with vehicle-treated control at each time point (days
1 and 7) (Fig. 2C and D). Vehicle treatment on day seven shows
elevated PSVueTM794 retention compared with that on day one
(Fig. 2C). This is most likely explained by the mechanism of
the probe. PSVueTM794 probe works by targeting phosphatidylserines exposed on the cell surface of apoptotic cells; however,
this probe cannot distinguish between apoptotic and necrotic
cell membranes in vivo. KcapQ647, a caspase-activatable probe,
allows for better discernment between apoptosis and necrosis.
Therefore, the increased PSVueTM794 signal in vehicle treated
tumors after 1 wk is most likely attributable to necrosis occurring in these tumors as they grow larger. As measured by the
KcapQ647 probe, treatment with IM shows decreased signal on
day 7 compared with that on day 1, while the PSVueTM794 probe
shows an increase in signal, again most likely a combination of
both apoptosis and necrosis detected by PSVueTM794 in these
tumors, with no significant change over time (Fig. 2C and D).
Immediately following FMT imaging, we performed MRI
scans to measure tumor volume. Due to the often flat and irregular
morphology of these GIST-T1 xenografts (Fig. 3A, white arrow),
we previously have found MRI tumor volume measurements to
be more precise than standard caliper measurements, and our
rapid MRI scanning protocol permits an efficient and cost effective method for obtaining these data. Not surprisingly, 24 h after
IM treatment no tumor shrinkage was observed in the IM-treated
cohort relative to their vehicle-treated counterparts (Fig. 3B, middle plot). These findings highlight the advantage of using the NIR
probes in combination with FMT imaging to detect apoptosis at
earlier time points, not possible with MRI, caliper measurements,
or any method that only measures tumor volume. At one week
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documented tumor response. FDG-PET metabolic response has
predicted RECIST response. The Choi criteria defines treatment
response as a >10% decrease in tumor size or a >15% decrease
in tumor density of tumor lesions assessed on contrast-enhanced
CT (CT) scans. Response by Choi criteria has been shown to correlate better with FDG-PET than standard RECIST response.6
A better understanding of imaging as it correlates with biologic
markers of response is needed; imaging that informs researchers
and clinicians more directly about cell death may be superior to
current techniques. IM has been previously shown to cause apoptosis in vitro in IM-sensitive cell lines.7-10 Therefore, in this study
we sought to evaluate the use of molecular imaging technology
using near-infrared (NIR) imaging probes in combination with
three-dimensional fluorescence molecular tomography (FMT)
for assessing therapeutic response and ultimately improving our
understanding of the biologic effects of these agents. Here, using
GIST-T1 xenografts, we evaluate the potential of two NIR probes
detecting two distinct markers of early apoptosis and compare
this to tumor size measured by magnetic resonance imaging
(MRI) in response to IM treatment.

©2014 Landes Bioscience. Do not distribute.
Figure 1. Detection of GIST with IntegriSense680 and treatment-related apoptosis with KcapQ647. Representative images of FMT imaging of GIST
xenografts treated with vehicle (top panel) or with IM (50 mg/kg) for 24 h (bottom panel). Images on the left are 2D reflectance images, in the middle,
the 3D FMT reconstruction of the αvβ3 signal used to delineate the region of interest (ROI) and on the right is the FMT signal from the cell-penetrating
KcapQ647 probe.
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post-treatment, a trend toward treatment-related shrinkage was
observed by MRI (Fig. 3B, third plot; Fig. 3C).
Finally, to validate these in vivo findings, immunohistochemical (IHC) analysis was performed ex vivo on tumors harvested
from the mice upon conclusion of the one week post-treatment

imaging. Tissue sections from all mice (n = 22) were stained for
markers of apoptosis, cleaved Lamin A and cleaved Caspase-3.
Histological examination demonstrated significant levels of both
apoptotic markers in the mice treated with IM compared with
their vehicle treated counterparts (Fig. 4).
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Figure 2. Quantification of IM-related apoptosis using NIR probes with FMT imaging. Change in apoptotic activity measured by the PSVueTM794 (A) and
KcapQ647 (B) probes between day 1 and day 7 of treatment with IM or vehicle control. Each measurement on apoptotic activity was normalized to its
corresponding tumor volume measurement obtained using MRI and expressed as a ratio (on the log-scale). A longitudinal model based on the generalized estimating equations approach was used to model the effect of treatment and time on apoptotic activity, adjusted for potential batch effects in
the experiment. Statistically significant increases in the rate of apoptotic activity due to IM treatment (compared with control) was observed (P value
= 1.41e−04 and 0.002, respectively) using data from the PSVueTM794 and KcapQ647 probes. Box-and-whisker plots of the apoptotic activity measured
by the PSVueTM794 (C) and KcapQ647 (D) probes on the logarithmic scale for various treatment-time combinations. In each plot, box height represents
the inter-quartile range (IQR) where the upper and lower ends indicate the third and first quartiles, respectively. The solid black horizontal line inside
the box represents the median value while the whiskers (the two solid horizontal lines at either end, connected by dotted lines) extend to the most
extreme data points which are no more than 1.5 times the IQR from the box in each direction. Using this criterion, points that lie beyond these whiskers
are considered to be outliers (open circles).

Discussion
Since the FDA approval of IM in 2002, the treatment of
GIST has radically improved. Advanced GIST, resistant to standard chemotherapy and radiation, can now be controlled initially
with IM in the majority of cases. However, these effects are often
short-lived, with IM demonstrating a median time to progression
of approximately 2 y. More recently, sunitinib and regorafenib
have been approved for second- and third-line options, though
both have PFS of less than 6 mo. In addition, there are currently
greater than 15 investigational agents being evaluated for the
management of GIST, including a number of small molecule
inhibitors of Hsp90 and IGF1R.11 With this wealth of agents
currently being investigated as well as the fact that researchers are
actively seeking out novel targets in GIST, it is becoming increasingly obvious that preclinical testing of these agents and/or novel
combinations of agents will be essential in discovering optimal
treatment regimens for GIST patients that have failed on the first
three lines of treatment.

Much of the effort, to date, involving preclinical evaluation of therapeutics in vivo for GIST has consisted of imaging
using small animal FDG-PET.12-16 Cullinane and colleagues
(2005) demonstrated, in a xenograft model using FDC-P1 cell
lines expressing either an IM-sensitive or -resistant KIT mutation, that IM led to a rapid reduction in FDG uptake on PET as
early as 4 h post-treatment in the IM-sensitive model.15 In 2010,
Revheim et al.14 showed decreased tumor-to-liver uptake ratios in
GIST xenografts 1 d and 8 d post-treatment with both IM and
sunitinib using a clinical PET/CT. Additionally, Pantaleo et al.
(2010) preclinically evaluated two additional small molecule
inhibitors, nilotinib and everolimus, in a GIST xenograft model,
as single agents or in combination with IM, using FDG-PET
imaging.13 This study demonstrated that all three single agents
led to decreased glucose uptake at 4 and 13 d post-treatment,
with the combination of IM and everolimus being superior to
all other treatment arms. Most recently, Floris and colleagues
demonstrated the successful combination of the PI3K inhibitor, GDC-0951, and IM in GIST xenografts using micro-PET
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Figure 3. Treatment-associated tumor shrinkage is not evident 24 h post IM treatment. (A) MR image showing GIST-T1 xenograft. (B) Box-and-whisker
plots of tumor volume (mm3) measured 7 d prior to treatment (first plot), 1 d post-IM treatment (middle plot), and 7 d post-IM treatment by MRI (last
plot). (C) Comparison of tumor volume change from 1 d post-treatment to 1 wk post-treatment between IM and vehicle-treated groups. P value is 0.094
using the Mann–Whitney test comparing the two differences IM day 7 − IM day 1 and vehicle day 7 − vehicle day 1. In all box plots, box height represents
the inter-quartile range (IQR) where the upper and lower ends indicate the third and first quartiles, respectively. The solid black horizontal line inside
the box represents the median value while the whiskers (the two solid horizontal lines at either end, connected by dotted lines) extend to the most
extreme data points which are no more than 1.5 times the IQR from the box in each direction. Using this criterion, points that lie beyond these whiskers
are considered outliers.

of agents at the molecular level. We hypothesize that using this
non-invasive approach in preclinical models of GIST has potential in evaluating new agents, combination of agents or varying
doses and dosing schedules and could allow us to assess the need
to change treatment regimens or discontinue their development
much earlier, when we see that there is no apoptosis induced by
the investigational therapy. Future studies evaluating novel therapies are planned to test this hypothesis.

Figure 4. IM treatment causes higher levels of apoptotic markers, cleaved caspase-3 and cleaved Lamin A, in GIST xenografts.
Immunohistochemistry of GIST-T1 xenografts, treated with vehicle (left
column) or with IM (right column) for one week, for cleaved caspase-3
(top row) and cleaved Lamin A (bottom row).

imaging.16 An alternative approach has recently been reported
using a fluorophore-conjugated anti-KIT antibody imaged by
fluorescence laparoscopy to detect and visualize cecal GISTs in
KIT K641E +/− transgenic mice.17 This approach yielded an accuracy of 92% in tumor detection and the authors speculate that
this method has future potential in disease response as well as
staging, evaluating tumor margin status, and identifying peritoneal metastases. It should be noted however, that the use of FDG
PET or the labeled anti-KIT antibody do not assess apoptosis of
cells.
Our study is a proof of concept demonstrating that in vivo
molecularly targeted imaging can be successfully used to evaluate
preclinical therapies non-invasively in GIST xenograft models.
We successfully show that two NIR probes, PSVueTM794 and
KcapQ647, can be used to quantify levels of apoptosis, as early
as 24 h post-IM treatment. These probes have varying mechanisms of action with PSVueTM794 targeting phosphatidylserines
exposed on the cell surface of both apoptotic and necrotic cells
membranes, whereas the cell-penetrating probe, KcapQ647,
possesses a cleavable domain (DEVD), a specific substrate for
caspase-3, that therefore can better distinguish apoptotic from
necrotic cells. KcapQ647 also has the advantage of a rapid and
potentially translatable optimal imaging time (1 h post injection)
compared with the other probes. Even with different mechanisms,
both probes were able to detect IM-related apoptosis, which was
subsequently confirmed by IHC staining of both cleaved Lamin
A and cleaved caspase-3. This approach is superior to standard
caliper tumor volume measurements, CT or MRI images, all of
which are commonly used in the GIST preclinical setting as a
readout of therapeutic efficacy, since this methodology allows for
rapid detection of cell death in response to drug. In addition,
we believe that this technology can be used preclinically as an
alternative to PET imaging to avoid the use of radionuclides and
to look at the effects of novel therapeutic agents or combination

GIST xenografts and drug administration
All studies involving animals followed procedures approved
by the Fox Chase Cancer Center Institutional Animal Care and
Use Committee. GIST-T1 cells, a tumor cell line possessing a heterozygous mutation in KIT exon 11 kindly provided by Takahiro
Taguchi,18 were washed and subsequently resuspended in phosphate-buffered saline (PBS) at a density of 3 × 106 cells/100 μL.
One hundred microliters of cells in PBS were mixed thoroughly
with 100 μL MatrigelTM Matrix (BD Biosciences) and the suspension was injected subcutaneously into the right flanks of
athymic nude mice (strain NCRNU, Taconic Inc.). Mice were
maintained on a standard diet (2018SX Teklad Global; Harlan
Laboratories) and transitioned to a purified, alfalfa-free rodent
chow (Teklad AIN76A; Harlan Laboratories) for a minimum of
48 h before imaging to minimize fluorescence in the gut, as well
as drinking water ad libitium. Tumor volumes were measured
twice weekly by MRI. When tumors reached approximately
300 mm3, mice were randomized into two groups. One group
was administered IM orally at 50 mg/kg daily and the second
group received only vehicle (sterile water).
Near-infrared fluorescent optical imaging agents
IntegriSense680 (PerkinElmer, Inc.), the αvβ3-targeted probe
detecting tumor-associated integrin receptor expression was utilized to determine tumor regions of interest (ROI).19 PSVueTM794
(Molecular Targeted Technologies), used as a marker of apoptosis, binds to phosphatidylserine residues exposed on the cell
surface of apoptotic cells and, in addition, binds to negativelycharged necrotic regions found in various tumors through its zinc
(II)-dipicolylamine (Zn-DPA).20,21 A third probe, KcapQ647
(synthesized in the laboratory of Dr. David Piwnica-Worms), a
cell-penetrating activatable probe was used to detect apoptosisassociated caspase activity.22-24
Magnetic resonance imaging
To accurately determine tumor volume, mice were imaged in
a 7 Tesla Vertical bore MRI system with a Bruker DRX spectrometer and Paravision 3.0.1 software. A T2 weighted RARE
(rapid acquisition of refocused echoes) pulse sequence provided
rapid imaging times and good delineation of tumor margins.
Twenty-six slices were acquired with MRI acquisition parameters: TR = 2300 msec, TE = 8.8 msec, rare factor = 8, effective
TE = 36.8 msec, nex = 2, slice thickness = 1 mm, field of view =
2.56 mm, acquisition matrix = 256 × 256, and imaging time of
2.5 min. During imaging, animals were anesthetized with 2%
isoflurane in O2. The total time to image one mouse, including
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animal preparation, was less than 10 min. Tumor volume was
measured with the Paravision 3.0 software by manually outlining
the tumor on each image slice where it appeared, and then summing the volumes from the individual slices. Because the subcutaneous tumors tended to have a relatively flat morphology, we
found the MRI measurements to be superior to estimating tumor
volume with calipers.
Fluorescence-molecular tomography (FMT)
In vivo FMT was performed with the VisEn FMT2500
Quantitative Tomography Imaging System (Perkin Elmer Inc.
Waltham, MA). FMT imaging was performed according to the
manufacturer’s standard procedures. Mice were anesthetized
with isoflurane (2% in O2), and placed in the bi-planar imaging
cassette supplied with the FMT2500. Mice were imaged in the
645 nm (KcapQ647), 680 nm (Integrisense680), and 750 nm
(PSVueTM794) channels. The FMT imaging times were of approximately 15 min duration for each mouse. Transmission and fluorescence images were captured with a thermo-electrically cooled
CCD camera. Three-dimensional volumetric FMT image sets
were reconstructed to an isotropic spatial resolution of 1 mm3, and
displayed with the TrueQuantTM software package supplied with
the FMT2500. A small dose (0.5 nmoles, approximately ¼ the
standard dose of 2 nmoles) of Integrisense680 (Perkin-Elmer) was
injected 96 h prior to imaging to mark the tumor position. Prior
work had indicated that in this model Integrisense680 imaged at
this time provided very accurate delineation of the tumors, with
very little background in the rest of the mouse. PSVueTM794 was
injected 18 h and KcapQ647 1 h prior to imaging. All probes
were injected retro-orbitally with an injection volume of 0.1 mL.
Images were analyzed with the Truquant software supplied with
the FMT imaging system.
Tissue preparation and immunohistochemical analysis
Upon conclusion of imaging, mice were euthanized by CO2
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